TDSGF (Telo Genomics) EV-to-EBIT : -3.03 (As of Jul. 12, 2025)

Telo Genomics EV-to-EBIT Chart

Telo Genomics Annual Data
	Trend	Dec14	Dec15	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24
EV-to-EBIT		Get a 7-Day Free Trial					-7.43	-19.23	-8.81	-6.51	-4.77

Telo Genomics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															-2.52	-4.77	-4.17	-4.51	-4.12

Competitive Comparison of Telo Genomics's EV-to-EBIT

For the Diagnostics & Research subindustry, Telo Genomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telo Genomics's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Telo Genomics's EV-to-EBIT falls into.

Telo Genomics EV-to-EBIT Calculation

Telo Genomics's EV-to-EBIT for today is calculated as:

Telo Genomics's current Enterprise Value is $5.65 Mil.
Telo Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics  (OTCPK:TDSGF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Telo Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Telo Genomics's Enterprise Value for the quarter that ended in Mar. 2025 was $5.19 Mil.
Telo Genomics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Telo Genomics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Telo Genomics Business Description